REG - Physiomics PLC - Options Award

PhysiomicsAnnouncement

23/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251223:nRSW5646Ma&default-theme=true

RNS Number : 5646M  Physiomics PLC  23 December 2025

23 December 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Options Award

 

Physiomics plc (AIM: PYC), announces an award of share options (the "Options")
over ordinary shares of 0.4 pence each in the capital of the Company
("Ordinary Shares"). The Company considers that it is important to incentivise
its key employees to create shareholder value and, as such, today the Board
has approved the award of the following options to Mr Jesse Thissen, Head of
Biometrics, under the Company's existing share option scheme (the "Scheme"):

1.   1,516,044 Options with an exercise price of 0.41 pence, representing a
41% premium to the closing mid-market price per Ordinary Share on 22 December
2025. All these Options vest on the first anniversary of Mr Thissen's
employment, being 1 July 2026.

2.   1,516,044 Options with exercise price of 0.79 pence, representing a
172% premium to the closing mid-market price per Ordinary Share on 22 December
2025. One third of these Options vest on each anniversary of Mr Thissen's
employment (33.3% from 1 July 2026, 66.7% from 1 July 2027 and 100% from 1
July 2028)

3.   1,516,044 Options with an exercise price of 1.29 pence, representing a
345% premium to the closing mid-market price per Ordinary Share on 22 December
2025. These Options vest over the same time periods as described under (2)
above.

All Options can be exercised within 10 years of the date of grant.

The total number of options issued to date under the Scheme is 4,548,132.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"As the Company pursues growth and a transition to cash generation, the
establishment of a scalable second service line represents a significant
milestone in this strategy. We are pleased to announce that following Jesse's
appointment in July 2025, he has played an integral role in launching our new
Biometrics service line. Within the first six months, he has secured and
commenced delivery on three contracts supporting new therapies for infectious
and immunological diseases. Jesse has demonstrated strong leadership in
advancing the Biometrics service line and continues to contribute effectively
across the broader organisation."

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGZMZZZZKGKZZ



            Copyright 2019 Regulatory News Service, all rights reserved